Renal protection with magnesium subcarbonate and magnesium sulphate in patients with epithelial ovarian cancer after cisplatin and paclitaxel chemotherapy: A randomised phase II study
Renal protection with magnesium subcarbonate and magnesium sulphate in patients with epithelial ovarian cancer after cisplatin and paclitaxel chemotherapy: A randomised phase II study
复制标题
DOI：
10.1016/j.ejca.2008.08.005
复制
发表时间：
2008-11-01
影响因子：
8.4
通讯作者：
Szczylik, Cezary
中科院分区：
文献类型：
--
作者：
Bodnar, Lubomir;Wcislo, Gabriel;Szczylik, Cezary
背景资料：本研究的目的是检查补充镁对上皮性卵巢癌（EOC）患者伴随标准顺铂化疗的肾毒性的影响。一项双盲安慰剂对照进行了一项随机研究，其中研究组在紫杉醇标准化疗的每个疗程前给予硫酸镁（5 g（135 mg/m2/24 h）联合顺铂（75 mg/m2），每3周一次。在治疗间隔期间，给予碱式碳酸镁（500 mg），每日3次口服。对照组给予安慰剂而不是两种镁盐。血清镁水平（sMg）和GFR标志物：在每个周期前和第6个疗程后3周记录血清肌酐（sCr）、Cockroft-Gault（CICG）和改良肾病饮食（MDRD）公式。sMg在补充组和安慰剂组之间差异显著（p
Background: The aim of this study was to examine the effect of magnesium supplementation on nephrotoxicity accompanying standard cisplatin-based chemotherapy in patients with epithelial ovarian cancer (EOC).Patients and methods: A double-blind, placebo-controlled, randomised study was conducted in which study arm magnesium sulphate (5 g) was administered before each course of standard chemotherapy with paclitaxel (135 mg/m(2)/24 h) plus cisplatin (7S mg/m(2)) every 3 weeks in patients with EOC. Magnesium subcarbonate (500 mg), three times per day orally, was administered during the treatment intervals. The control arm was administered a placebo instead of both magnesium salts. Magnesium serum levels (sMg) and GFR markers: serum levels of creatinine (sCr), Cockroft-Gault (CICG) and Modification Diet of Renal Disease (MDRD) formulae were recorded before each cycle, and 3 weeks after the sixth course.Results: 41 EOC patients were randomised and 40 were eligible. sMg varied significantly between the supplemented and placebo groups (p